2011, Number 1
<< Back Next >>
Rev Med MD 2011; 2.3 (1)
Gota
Sandoval-Castro CE, Padilla-Ibarra J
Language: Spanish
References: 27
Page: 16-22
PDF size: 970.70 Kb.
ABSTRACT
Gout, is one of the most antique and complex diseases known and it has doubled its prevalence in recent years, specially in the
United States and other developed countries, due to the increased number of multiple comorbidities, advanced age,
hyperuricemia, diet and life style factors. Indeed, the more we know about this disease, the more complex it becomes. This
Review has different objectives; to understand the importance of risk factors for developing gout and to review the last decade
advances in treatment. Making emphasis in the employment of dietry measures and pharmacologic treatments for active gouty
arthritis. Not only focused in the disease treatment but also, and most importantly, in the prevention of gout flares and the
importance of lowering hyperuricemia levels. In addition, new techniches for the developing of tophus in order to analyze how
this can make a difference in the treatment and the patient's follow up. A revision among the newest therapies for the managment
of acute flares, such as febuxostat and pegylated uricase urate-lowering theraphy, just recently approved on September 2010 by
the FDA for gout treatment. Hoping that this review helps their readers comprehend the complexity of this disease, and helping
lead the managment of hyperuricemia and gout, reducing risk and having improvements in patient-centered outcomes.
REFERENCES
1.Iglesias-Gamarra A., Quintana L. Gerardo, Restrepo Suárez José Felix,Prehistoria, historia y arte de la Reumatología Gota y espondilitis anquilosante”, Revista Colombiana de Reumatología, Junio 2006; Vol 13, pp 120-141
2.Tuhina Neogi, Gout. N Engl J Med 2011; 364:443-452
3.Anne-Kathrin Tausche, Tim L. Jansen, Gout- Current Diagnosis and Treatment”, Dtsch Arztebl, Int 2009; 106(34–35): 549–55 DOI: 10.3238/arztebl.2009.0549
4.Luk A, Simkin P, “Epidemiology of Hyperuricemia and Gout The American Journal of Managed Ca, Noviembre 2005; Vol 11, pp 143-152
5.Terkeltaub RA. Gout. N Engl J Med 2003;349:1647-165
6.Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G “Purine-rich foods, dairy and protein intake, and the risk of gout in men”.N Engl J Med. 2004;350: 1093-1103.
7.So A., Thorens B. Uric acid transport and disease, The Journal of Clinical Investigation Volume 120 Number 6 June 2010
8.Philip L. Riches,_, Alan F. Wright and Stuart H. Recent insights into the pathogenesis of hyperuricaemia and gout Human Molecular Genetics, 2009, Vol. 18, Review Issue 2
9.Terkeltaub, RA. Update on gout: new therapeutic strategies and options Nat. Rev. Rheumatol. 2010;6 :30–38.
10.Garrod, AB. The Nature and Treatment of Gout and Rheumatic Gout, 2nd edition, 1863.
11.Freudweiler, M. Experimental investigations into the origin of gouty tophi. Arthritis Rheum 1965; 19:267
12.Neven B et al.“Cryopyrinopathies: update on pathogenesis and treatment” september 2008 vol 4 no 9.
13.Falasca GF; Ramachandrula A; Kelley KA; O'Connor CR; Reginato AJ Superoxide anion production and phagocytosis of crystals by cultured endothelial cells. Arthritis Rheum 1993 Jan;36(1):105-16.
14.Yagnik DR; Evans BJ; Florey O; Mason JC; Landis RC; Haskard DO Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004 Jul;50(7):2273-80
15.Akahoshi T; Namai R; Murakami Y; Watanabe M; Matsui T; Nishimura A; Kitasato H; Kameya T; Kondo H Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum 2003 Jan;48(1):231-9.
16.Ortiz-Bravo E; Sieck MS; Schumacher HR Jr Changes in the proteins coating monosodium urate crystals during active and subsiding inflammation. Immunogold studies of synovial fluid from patients with gout and of fluid obtained using the rat subcutaneous air pouch model. Arthritis Rheum 1993 Sep;36(9):1274-85.
17.H.Ralph Schumacher Jr, MD,The pathogenesis of gout Cleveland Clinic Journal of Medicine Volume 75 Supplement 5 July 2008
18.Perez-Ruiz, Fernando, Dalbeth, Nicola, Urresola, Aranzazu, de Miguel, Eugenio y Schlesinger, Naomi. “Imaging of gout: findings and utility”. Arthritis Research & Therapy 2009, 11:232 (doi:10.1186/ar2687)
19.H K Choi, A M Al-Arfaj, A Eftekhari, P L Munk, K Shojania, G Reid, S Nicolaou. “Dual energy computed tomography in tophaceous gout”. Ann Rheum Dis 2009;68:1609–1612.
20.Choi HK, Atkinson K, Karlson EW, Willett W,Curhan G. “Alcohol intake and risk of incident gout in men: a prospective study.” Lancet. 2004;363:1277-1281.
21.Fernandez, C, Noguera, R, Gonzalez, JA, Pascual, E. Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26:228
22.Janssens HJ; Janssen M; van de Lisdonk EH; van Riel PL; van Weel C Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60.
23.Getting SJ; Christian HC; Flower RJ; Perretti M Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 2002 Oct;46(10):2765-75
24.Martinon F; Petrilli V; Mayor A; Tardivel A; Tschopp J Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006 Mar 9;440(7081):237-41. Epub 2006 Jan 11.
25.Pascual E. , Sivera F., “ Febuxostat”. Fresh from pipeline Nature Reviews Drug Discovery volume 8 march 2009.
26.Schlesinger N. “Pegloticase” fresh from pipeline Nature Reviews Drug Discovery Volume 10, January 2011.
27.US Food and Drug Administration. FDA labeling information — Krystexxa (pegloticase). Revisado el:17 octubre de 2011. Disponible en: http://www. accessdata. fda. gov/drugsat fda_docs/label/2010/125293s0000lbl.pdf
Full text